PTC/SB/06s (08-03.)
Approved for use through 97/31/2006, ONE 0651-0331
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

Approved for use innough of 731 (2006) CMIND (651-4)

U.S. Patent and Trademank Office; U.S. DEPARTMENT OF COMME!

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information uniformation uniformation uniformation uniformation uniformation.

	Application Number			
	Filing Date		2006-05-09	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Bruno	Bret	
(Not for submission under 37 CFR 1.99)	Art Unit			
,	Examiner Name			
	Attorney Docket Number	er	20147 - 434 PCT	

					U.S.	PATENTS			Remove		
Examiner Initial*	ner Cite No Patent Number Kind Code1 Issue Date Name of Patentee or Au of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear							
	1										
If you wis	h to a	l dd additional U.S. Pate	nt citatio	n inform	ation pl	l lease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee of Applicant Re		Releva		Lines where ges or Relev	
	1										
If you wis	h to a	dd additional U.S. Publ	shed Ap					d button	Add		
	_			FOREIG	SN PAT	ENT DOCUM	IENTS				_
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	vhere Rel	or Relevant	+4
	1	1103040	GB		A	1968-02-14	Procter & Gamble				
	2	54035215	JP		A	1979-03-15	Kusano K				
	3	97/30217	wo		A1	1997-08-21	Kaysersberg				

	Application Number		
NEODMATION DIOCE COURT	Filing Date		2006-05-09
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Brun	Bret
Not for submission under 37 CFR 1.99)	Art Unit		
,	Examiner Name		
	Attorney Docket Numb	er	20147 - 434 PCT

If you wisl	h to a	dd add	ditional Foreign Patent Document citation information please click the Add buttor	Add	
			NON-PATENT LITERATURE DOCUMENTS	Remove	
Examiner Initials*	Cite No	(bool	de name of the author (in CAPITAL LETTERS), title of the article (when approprik, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-is sher, city and/or country where published.		Ţ5
	1				
If you wis	h to a	dd add	ditional non-patent literature document citation information please click the Add b	outton Add	-
			EXAMINER SIGNATURE		
Examiner	Signa	ture	Date Considered		
			reference considered, whether or not citation is in conformance with MPEP 609. rmance and not considered. Include copy of this form with next communication		

1 See Kind Coden of USPTO Patent Documents at work USPTO_CODY or MPEP 90.04. 2 Enter office that issued the document, by the hin-eleter code (WIPO Standard ST3.) 3 "For Junganees patent counters, the included not on the year of the insperior impreced the sent included the patent document. 4 Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST.16 if possible. 3 Applicant is to place a check mark here if Enginth language the instation is attached.

Application Number Filing Date 2006-05-59 Filing Date 2006-05-59 First Number Investment Brune Bret Art Unit Examiner Name Attorney Docket Number 20147 - 434 PCT

CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. Sec 37 CFR 197(eV1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Please see 37 CFR 1 97 and 1 98 to make the appropriate selection(s):

7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Robert S. Alexander/	Date (YYYY-MM-DD)	2006-05-09
Name/Print	Robert S. Alexander	Registration Number	28359

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant Afford, U.S. Department of Commence, P. 0. Bast 1436, Alexandria, V.32.11.445, D. ON TS END FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.32.213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.